Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2020 Dec 02

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Panminerva Medica 2020 Dec 02

DOI: 10.23736/S0031-0808.20.04170-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Inhibition against p38/MEF2C pathway by Pamapimod protects osteoarthritis chondrocytes hypertrophy

Jian ZHANG 1, Chen YAN 1, Weidong HE 1, Min WANG 2, Jian LIU 1

1 Department of Orthopaedics, The First People’s Hospital of Lianyungang, Lianyungang, China; 2 Department of Medicine, The First People’s Hospital of Lianyungang, Lianyungang, China


PDF


BACKGROUND: The p38 mitogen-activated protein kinase pathway plays an important role in the pathogenesis of osteoarthritis (OA) involving in hypertrophy, calcification, and apoptosis of chondrocytes (CHs). In this study, we focused on a p38 inhibitor named Pamapimod (PAM) in the effect of CH hypertrophy degeneration.
METHODS: CHs were isolated from the cartilage collected from OA patients. Insulin-Transferrin-Selenium (ITS) medium was used as a hypertrophic inducer to establish CH hypertrophy model. Asiatic acid (AA) was used to activate p38 phosphorylation. We transfected CHs with myocyte enhancer factor 2C (MEF2C)-plasmid to upregulate MEF2C expression. Chondrogenic gene expression such as type II collagen and SOX-9, and hypertrophic genes such as type X collagen, MMP-13, and Runx-2 were analyzed by western blot, RT-PCR or immunofluorescence.
RESULTS: ITS and AA all contributed to the CHs hypertrophy with an upregulation of p-p38 and MEF2C protein expression. PAM treatments significantly inhibited p-p38 and MEF2C expression, down-regulated type X collagen, MMP-13, and Runx-2 expression and upregulated type II collagen and SOX-9 levels. PAM indirectly affected MEF2C expression and resulted in CHs hypertrophy suppression.
CONCLUSIONS: PAM protects CHs hypertrophy by the inhibition of the p38/MEF2C pathway.


KEY WORDS: p38; MEF2C; Chondrocyte; Hypertrophy; Osteoarthritis

inizio pagina